Our people are vital to our success.
Our people are vital to our success.
Our highly differentiated team are experts at what they do. Our life sciences investment team members have deep technical scientific background, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch. This skill set has resulted in a strong network in life science, enabling the best talent to be attracted at the level of Syncona's portfolio companies.
Chief Executive Officer
Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust.
Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Autolus, Quell and Anaveon and is a Director of Resolution. He was previously Chairman of Blue Earth Diagnostics, which Syncona sold to Bracco Imaging for $476 million in 2019.
Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.
Chief Investment Officer
Chris is the Chief Investment Officer of Syncona Investment Management Ltd.
He has been instrumental in the foundation and development of Syncona's gene therapy strategy, where it has founded companies focused on the eye, the liver, the kidney, and central nervous system. He is Chairman of Freeline, Gyroscope, SwanBio and Purespring and was also previously Chairman of Nightstar, a retinal gene therapy company founded by Syncona which was sold to Biogen in 2019 for $877 million.
Previously, Chris was a partner of Apposite Capital LLP, a venture and growth capital healthcare investment company. Before Apposite, Chris had roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Chief Financial Officer
John Bradshaw is the Chief Financial Officer of Syncona Investment Management Ltd.
John has worked extensively with companies in the life science sector as a part-time and interim CFO. He was previously CFO of Gyrus Group PLC and qualified as a chartered accountant with Arthur Andersen. John has a degree in Law from the University of Liverpool.
Freddie is a Partner of Syncona Investment Management Ltd.
He has been closely involved with Quell Therapeutics where he spent a year as Director of Operations and serves as an Observer on the Board. Previously, he was a member of the Investment Team at the Wellcome Trust, which is responsible for the management of its £23 billion global investment portfolio. Freddie holds a degree in Biochemistry from the University of Edinburgh.
Executive in Residence
Ken is Executive in Residence at Syncona Investment Management Ltd.
Ken has over 30 years’ experience in biotechnology and venture capital having worked as a life sciences executive, director, investor and advisor across North America in the growth of both private and NASDAQ-listed companies from an early-stage through commercialisation. He was the Chief Financial Officer at QLT, Canada’s first biotechnology company until 2000.
Ken has almost a decade of experience in the management of venture capital funds and new company formation and has worked with many biotechnology companies including: Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, and Aquinox among others.
Gonzalo is a Partner of Syncona Investment Management Ltd.
He is currently also Chief of Staff at Resolution Therapeutics and serves an Observer on the Board. Previously, Gonzalo was a Project Leader at Boston Consulting Group where, amongst other responsibilities, he supported clients in the biopharmaceuticals industry across the entire value chain. Gonzalo has an interdisciplinary background, including a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and a Master’s degree in Physics.
Alex is a Partner of Syncona Investment Management Ltd.
He is a Director on the Board of SwanBio Therapeutics. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from the University of Cambridge.
Edward Hodgkin is a Partner of Syncona Investment Management Ltd.
He is currently Chairman & CEO of Resolution Therapeutics and Chairman of OMass Therapeutics, and was previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL). Within the Syncona life science team, he is involved in creation of new businesses and then fills executive roles within those companies to make them operational.
Prior to Syncona, he was CEO of Biotica Ltd (Cambridge, UK), President & Chief Business Officer of BrainCells Inc (San Diego, CA), and VP, Business Development & Marketing at Tripos Inc (St Louis, MO). Ed’s early career was spent in research and management positions with Wyeth-Ayerst Inc and British Biotech. He holds a degree and DPhil in Chemistry from the University of Oxford, and is a former Chairman of the BIA, the UK’s trade association for innovative life science companies.
Magdalena is a Partner of Syncona Investment Management Ltd.
She is a Director on the Board of Omass Therapeutics. Previously, she was an Associate Partner at McKinsey & Company where she specialised in pharmaceuticals Research & Development, portfolio management and Business Development and Licensing. Magdalena holds a PhD in Bioengineering from Stanford University and was a postdoctoral fellow in Harvard Medical School’s Computational Health Informatics Programme.
Michael Kyriakides is a Partner of Syncona Investment Management Ltd.
He works closely with Syncona portfolio companies Freeline Therapeutics and Gyroscope Therapeutics
Previously, Michael was a member of the Life Sciences team at L.E.K. Consulting, where he worked in projects for pharmaceutical, biotech and private equity clients. Prior to joining L.E.K. Consulting, he was a clinical project and NMR manager in the Faculty of Medicine at Imperial College London. Michael obtained his doctorate degree in toxicology and metabolic profiling at Imperial College London.
Entrepreneur in Residence
Lorenz is an Entrepreneur in Residence at Syncona Investment Management Ltd.
Previously, he was the Chief Technology Officer for GE Healthcare Life Sciences, overseeing R&D investment, research programmes and business growth strategy. Prior to this he held senior leadership positions at Novartis, Astra Zeneca and Bayer. He also holds a position as a Visiting Scientist/Guest Professor at the ETHZ, the Swiss Federal Institute of Technology at Zurich/Switzerland.
Elisa is a Partner of Syncona Investment Management Ltd.
She is a Director on the Board of Quell Therapeutics and Neogene Therapeutics and was previously on the Board of former portfolio company Blue Earth Diagnostics. She was closely involved in the foundation of both Quell and Blue Earth, including their operational and strategic set-up.
Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K. Consulting based in London. While at L.E.K. she worked on projects for biotech, pharma and private equity clients. Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.
Alice is a Partner of Syncona Investment Management Ltd.
She is also currently Head of Operations at Purespring Therapeutics andworks closely with Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon.
Prior to joining Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare Corporate Finance and M&A team, where she worked on transactions involving pharmaceutical and other healthcare companies. Prior to Barclays, Alice worked briefly at AbbVie and Janssen. Alice holds a Doctorate degree in Pharmacy from the University of Lille 2 (School of Pharmacy, Lille, France). She holds a Masters in International Health Policy & Health Economics from the London School of Economics.
Dominic is a Partner of Syncona Investment Management Ltd.
He is a a Director on the board of Anaveon, and Purespring Therapeutics.
Prior to joining Syncona, Dominic worked in the life science practice of strategy consultancy L.E.K Consulting. He received his PhD from the Department of Oncology at the University of Cambridge where he was a Cancer Research UK scholar. He also holds a German Diplom Degree in Biochemistry and his research has been honoured with national and international prizes and published in Cell, Nature and Science.
Hitesh is a Partner of Syncona Investment Management Ltd.
He has 24 years’ experience of global public equities. He managed Innovation funds for several asset management companies including Aviva and ADIA, where he was a top-rated portfolio manager. He has an interest in the convergence of life science with other innovationled sectors such as data sciences and the application of industrial technology in medical diagnostics. He has a degree in Chemistry from King’s College London and is a CFA.
Andrew is the General Counsel of Syncona Investment Management Ltd.
Previously, he was Chief Investment Counsel at the Wellcome Trust, responsible for legal issues arising from its £23bn global multi-asset investment portfolio, and where he was involved in the initial formation of Syncona Partners LLP. Prior to that he worked as a corporate lawyer in London and Edinburgh.
Andrew has an LLB from the University of Glasgow.
Nisha Sethi is the Legal Counsel at Syncona Investment Management Limited.
Previously, Nisha worked as Legal Counsel for Animo Associates Limited, a corporate service provider specialising in compliance and management consulting advice. Prior to this, Nisha qualified at Noble Solicitors which is where she spent 5 years predominantly specialising in criminal defence law. Nisha holds an LLB from the University of Reading.
Amisha is a Management Accountant at Syncona Investment Management limited
Amisha has over a decade of Accounting experience with focuses in Marketing and Advertising industries. Her educational background includes a Masters degree in Commerce from Gujarat University, India and she is on route to completing her ACCA Chartership.
Stephen is Financial Controller at Syncona Investment Management Ltd
He is a CIMA qualified accountant with over ten years’ experience in 3rd Sector and FTSE 100 finance teams. Most recently he worked in FP&A and Commercial Finance at the Wellcome Trust, providing internal business support and financial oversight of Wellcome’s grant funding recipients. Prior to that he worked at Sky in roles supporting product development and sales & marketing. He has an MSc in International Business & Management from Manchester Business School and an undergraduate degree in Business Studies from Trinity College Dublin.
Head of Finance
Nikki is Head of Finance at Syncona Investment Management Ltd
She is a chartered accountant with experience in practice and commerce. Previous roles include business operations at GlaxoSmithKline and project management for AEA Technology and its biopharmaceutical contract manufacturing spin-out. Prior to this she worked in research at King’s College, London and the University of Reading. Nikki has a PhD in Biotechnology from King’s College and an MBA from Warwick Business School.
Christina is Group Accountant at Syncona Investment Management Limited.
Christina is a Chartered Accountant having trained at Deloitte LLP, spending 5 years in practice before joining Syncona. Prior to that she obtained her BSc in Biomedical Sciences from the University of Warwick
David Twumasi is an Accountant at Syncona Investment Management Limited.
He has previously worked in Media and judiciary Service companies covering similar areas of work. He has a science background through his BSc in Biomedical Science from the University of Kent and has since gained a degree in Accounting as he works towards his ACCA Chartership.
Head of Investor Relations
Annabel is Head of Investor Relations at Syncona Investment Management Ltd
Previously, she was a Consultant at Greenbrook Communications, advising clients on a wide range of projects and transactions. Prior to that, Annabel spent several years at a leading financial communications firm, where she worked with companies across a number of sectors. She has an Honours Degree in History from the University of Bristol.
Head of Corporate Affairs
Siobhan Weaver is Head of Corporate Affairs at Syncona Investment Management Ltd.
Previously, she worked at Tulchan Communications, a financial communications agency, where she was a Director providing advice to a range of clients across a wide range sectors, projects and transactions. Siobhan has spent almost a decade in financial communications, having previously worked for one of the leading consultancies in Australia. She has degrees in Law and Media Communications from the University of Melbourne.
Fiona is the Office Manager of Syncona Investment Management Ltd overseeing the daily operations of the office and supporting a number of the partners.
Prior to joining Syncona, Fiona held various senior support roles, most recently as an Executive Assistant at AnaCap Financial Partners, supporting two of the Partners, Legal Counsel and the Mergers and Acquisitions team.
Fiona holds a degree in Geography and Management from Leeds University.
Caroline is an Executive Assistant at Syncona Investment Management Ltd supporting the CEO, Chairman and Investor Relations team.
Prior to joining Syncona, Caroline held senior support roles in a number of sectors, most recently at Odgers Berndtson where she supported the Global Head of Marketing and Head of Research.
Caroline holds a Joint Honours degree in Hispanic Studies and History from the University of Nottingham.
Katie Trafford is a Team Assistant at Syncona Investment Management Limited.
Prior to joining Syncona, Katie was a Personal Assistant to Finance Directors at Wellcome Trust. Katie has over five years financial PA experience after graduating from Oxford Media & Business School.